196 related articles for article (PubMed ID: 31071511)
1. Therapeutic effects of curcumin and ursodexycholic acid on non-alcoholic fatty liver disease.
Gheibi S; Gouvarchin Ghaleh HE; Motlagh BM; Azarbayjani AF; Zarei L
Biomed Pharmacother; 2019 Jul; 115():108938. PubMed ID: 31071511
[TBL] [Abstract][Full Text] [Related]
2. Protective effect of ursodeoxycholic acid, resveratrol, and N-acetylcysteine on nonalcoholic fatty liver disease in rats.
Ali MH; Messiha BA; Abdel-Latif HA
Pharm Biol; 2016 Jul; 54(7):1198-208. PubMed ID: 26134756
[TBL] [Abstract][Full Text] [Related]
3. Omega-3 polyunsaturated fatty acid and ursodeoxycholic acid have an additive effect in attenuating diet-induced nonalcoholic steatohepatitis in mice.
Kim JK; Lee KS; Lee DK; Lee SY; Chang HY; Choi J; Lee JI
Exp Mol Med; 2014 Dec; 46(12):e127. PubMed ID: 25523099
[TBL] [Abstract][Full Text] [Related]
4. Protective effects of tiopronin against high fat diet-induced non-alcoholic steatohepatitis in rats.
Wang JQ; Zou YH; Huang C; Lu C; Zhang L; Jin Y; Lü XW; Liu LP; Li J
Acta Pharmacol Sin; 2012 Jun; 33(6):791-7. PubMed ID: 22543705
[TBL] [Abstract][Full Text] [Related]
5. Ursodeoxycholic acid alleviates nonalcoholic fatty liver disease by inhibiting apoptosis and improving autophagy via activating AMPK.
Wu P; Zhao J; Guo Y; Yu Y; Wu X; Xiao H
Biochem Biophys Res Commun; 2020 Aug; 529(3):834-838. PubMed ID: 32595039
[TBL] [Abstract][Full Text] [Related]
6. Ursodeoxycholyl Lysophosphatidylethanolamide modifies aberrant lipid profiles in NAFLD.
Pathil A; Liebisch G; Okun JG; Chamulitrat W; Schmitz G; Stremmel W
Eur J Clin Invest; 2015 Sep; 45(9):925-31. PubMed ID: 26108973
[TBL] [Abstract][Full Text] [Related]
7. Ursodeoxycholic acid: Effects on hepatic unfolded protein response, apoptosis and oxidative stress in morbidly obese patients.
Mueller M; Castro RE; Thorell A; Marschall HU; Auer N; Herac M; Rodrigues CMP; Trauner M
Liver Int; 2018 Mar; 38(3):523-531. PubMed ID: 28853202
[TBL] [Abstract][Full Text] [Related]
8. New evidence for the therapeutic potential of curcumin to treat nonalcoholic fatty liver disease in humans.
Inzaugarat ME; De Matteo E; Baz P; Lucero D; García CC; Gonzalez Ballerga E; Daruich J; Sorda JA; Wald MR; Cherñavsky AC
PLoS One; 2017; 12(3):e0172900. PubMed ID: 28257515
[TBL] [Abstract][Full Text] [Related]
9. Hepatoprotective effects of Shilajit on high fat-diet induced non-alcoholic fatty liver disease (NAFLD) in rats.
Ghezelbash B; Shahrokhi N; Khaksari M; Ghaderi-Pakdel F; Asadikaram G
Horm Mol Biol Clin Investig; 2020 Feb; 41(1):. PubMed ID: 32083445
[TBL] [Abstract][Full Text] [Related]
10. Ursodeoxycholic acid ameliorates hepatic lipid metabolism in LO2 cells by regulating the AKT/mTOR/SREBP-1 signaling pathway.
Hu J; Hong W; Yao KN; Zhu XH; Chen ZY; Ye L
World J Gastroenterol; 2019 Mar; 25(12):1492-1501. PubMed ID: 30948912
[TBL] [Abstract][Full Text] [Related]
11. Hepatoprotective and antioxidant effects of lycopene on non-alcoholic fatty liver disease in rat.
Jiang W; Guo MH; Hai X
World J Gastroenterol; 2016 Dec; 22(46):10180-10188. PubMed ID: 28028366
[TBL] [Abstract][Full Text] [Related]
12. Effect of curcumin on visfatin and zinc-α2-glycoprotein in a rat model of non-alcoholic fatty liver disease.
Li C; Li J; Chen Y; Zhong X; Kang M
Acta Cir Bras; 2016 Nov; 31(11):706-713. PubMed ID: 27982256
[TBL] [Abstract][Full Text] [Related]
13. Protective effect and mechanism of Qiwei Tiexie capsule on 3T3-L1 adipocytes cells and rats with nonalcoholic fatty liver disease by regulating LXRα, PPARγ, and NF-κB-iNOS-NO signaling pathways.
Suolang PC; Liu BQ; Chen J; De J; Nima ZB; Dunzhu CR
J Ethnopharmacol; 2019 May; 236():316-325. PubMed ID: 30851372
[TBL] [Abstract][Full Text] [Related]
14. Hepatoprotective Effect of Seed Coat ofEuryale ferox Extract in Non-alcoholic Fatty Liver Disease Induced by High-fat Diet in Mice by Increasing IRs-1 and Inhibiting CYP2E1.
Jian T; Yu C; Ding X; Chen J; Li J; Zuo Y; Ren B; Lv H; Li W
J Oleo Sci; 2019 Jun; 68(6):581-589. PubMed ID: 31092797
[TBL] [Abstract][Full Text] [Related]
15. Does propolis have any effect on non-alcoholic fatty liver disease?
Kismet K; Ozcan C; Kuru S; Gencay Celemli O; Celepli P; Senes M; Guclu T; Sorkun K; Hucumenoglu S; Besler T
Biomed Pharmacother; 2017 Jun; 90():863-871. PubMed ID: 28437890
[TBL] [Abstract][Full Text] [Related]
16. Ameliorative effect of nicorandil on high fat diet induced non-alcoholic fatty liver disease in rats.
Elshazly SM
Eur J Pharmacol; 2015 Feb; 748():123-32. PubMed ID: 25542756
[TBL] [Abstract][Full Text] [Related]
17. miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease.
Castro RE; Ferreira DM; Afonso MB; Borralho PM; Machado MV; Cortez-Pinto H; Rodrigues CM
J Hepatol; 2013 Jan; 58(1):119-25. PubMed ID: 22902550
[TBL] [Abstract][Full Text] [Related]
18. Is There a Role for Curcumin Supplementation in the Treatment of Non-Alcoholic Fatty Liver Disease? The Data Suggest Yes.
Zabihi NA; Pirro M; Johnston TP; Sahebkar A
Curr Pharm Des; 2017; 23(7):969-982. PubMed ID: 27748192
[TBL] [Abstract][Full Text] [Related]
19. Antioxidant mechanism of hepatoprotection by ursodeoxycholic acid in experimental alcoholic steatohepatitis.
Lukivskaya O; Zavodnik L; Knas M; Buko V
Adv Med Sci; 2006; 51():54-9. PubMed ID: 17357278
[TBL] [Abstract][Full Text] [Related]
20. Clinical effect of the extract of TCM Fructus akebiae combined with ursodeoxycholic acid on nonalcoholic fatty liver disease.
Hongguang J; Xingjie H; Mingliang J; Yun L; Tongjian L; Jingmo Y; Liang L; Lifang Z
Pak J Pharm Sci; 2019 Jan; 32(1(Special)):433-437. PubMed ID: 30852481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
